1
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               AMENDMENT NO. 5 TO
                                  SCHEDULE 13D

                  Under the Securities Exchange Act of 1934



                                  MetLife, Inc.
                                (Name of Issuer)


                    Common Stock, par value $.01 per share
                         (Title of Class of Securities)


                                    59156R108
                                 (CUSIP Number)


                             Gary A. Beller, Esq.
             Senior Executive Vice-President and General Counsel
                                  MetLife, Inc.
                               One Madison Avenue
                             New York, NY 10010-3690
                                 (212) 578-2211
 (Name, Address and Telephone Number of Person Authorized to Receive Notices
                             and Communications)


                                  May 15, 2001
           (Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(3), 240.13d-1(f) or 240.13d-1(g),
check the following box [ ].

Note:  Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits.  See Section 240.13d-7(b)
for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
   2
                                  SCHEDULE 13D



CUSIP No. 59156R108                                                        Page 2 of 9 Pages
                                       
--------------------------------------------------------------------------------------------

(1)   Names of Reporting Persons          Board of Directors of MetLife, Inc., as an entity

      S.S. or I.R.S. Identification
      Nos. of Above Persons               Not applicable
--------------------------------------------------------------------------------------------

(2)   Check the Appropriate Box                                         (a)  [  ]
      if a Member of a Group                                            (b)  [  ]

--------------------------------------------------------------------------------------------

(3)   SEC Use Only

--------------------------------------------------------------------------------------------

(4)   Source of Funds                                             Not Applicable. See Item 4

--------------------------------------------------------------------------------------------

(5)   Check if Disclosure of Legal
      Proceedings is Required Pursuant
      to Items 2(d) or 2(e)                                                             [  ]

--------------------------------------------------------------------------------------------

(6)   Citizenship or Place of
      Organization                                                                    U.S.A.

--------------------------------------------------------------------------------------------

Number of Shares                          (7) Sole Voting Power                            0
Beneficially Owned
by Each Reporting                         --------------------------------------------------
Person With
                                          (8) Shared Voting Power               442,894,415*

                                          --------------------------------------------------

                                          (9) Sole Dispositive Power                       0

                                          --------------------------------------------------

                                         (10) Shared Dispositive Power                    0

--------------------------------------------------------------------------------------------

(11)  Aggregate Amount Beneficially
      Owned by Each Reporting Person                                             442,894,415

--------------------------------------------------------------------------------------------

(12)  Check if the Aggregate Amount
      in Row (11) Excludes Certain Shares                                              [   ]
--------------------------------------------------------------------------------------------

(13)  Percent of Class Represented
      by Amount in Row 11                                                              59.1%
--------------------------------------------------------------------------------------------

(14)  Type of Reporting Person                                                            OO
--------------------------------------------------------------------------------------------


* Unless otherwise indicated, all information relating to beneficial ownership
of the Shares by the Reporting Persons is as of April 30, 2001.
   3
                                  SCHEDULE 13D

CUSIP No. 59156R108                                           Page 3 of 9 Pages


Items 4 and 5 are amended as set forth below:

ITEM 4.     PURPOSE OF TRANSACTION.

            The Board of Directors is reporting beneficial ownership of
442,894,415 shares of Common Stock (the "Shares") held by the MetLife
Policyholder Trust (the "Trust") under the Plan of Reorganization, dated
September 28, 1999, as amended (the "Plan"), of Metropolitan Life Insurance
Company ("MetLife").

            On April 7, 2000, 494,466,664 Shares were issued to the Trust
pursuant to Section 5.2(d) of the Plan, a copy of which is filed as an exhibit
to this statement. No consideration has been separately provided therefor by any
member of the Board of Directors, except for Shares allocated to such member
pursuant to the Plan. Since April 7, 2000, transactions by Beneficiaries under
the Purchase and Sale Program provided for by the Trust Agreement (as defined
below) have resulted in a decrease in the number of Shares held by the Trust
from 494,466,664 to 442,894,415.

            Under the Plan and the MetLife Policyholder Trust Agreement, dated
as of November 3, 1999 (the "Trust Agreement"), by and among MetLife, the
Issuer, Wilmington Trust Company (the "Trustee") and ChaseMellon Shareholder
Services, L.L.C., as custodian (the "Custodian"), a copy of which is attached as
an exhibit to this statement, certain eligible policyholders of MetLife ("Trust
Eligible Policyholders") have been allocated a number of interests in the Trust
("Trust Interests") equal to the number of shares of Common Stock allocated to
the Trust Eligible Policyholders in accordance with the Plan. The assets of the
Trust principally are the Shares issued to the Trust for the benefit of the
Trust Eligible Policyholders and permitted transferees (collectively, the
"Beneficiaries"). The Shares are held in the name of the Trustee, on behalf of
the Trust, which has legal title over the Shares. The Beneficiaries do not have
legal title to any part of the assets of the Trust. The Trust Interests
represent undivided fractional interests in the Shares and other assets of the
Trust beneficially owned by a Trust Beneficiary through the Custodian.

            The Trust Agreement provides the Trustee with directions as to the
manner in which to vote, assent or consent the Shares at all times during the
term of the Trust. On all matters brought for a vote before the stockholders of
the Issuer, with the exception of a Beneficiary Consent Matter (as defined
below), the Trustee will vote in accordance with the recommendation given by the
Board of Directors of the Issuer to its stockholders or, if no such
recommendation is given, as directed by the Board. On all Beneficiary Consent
Matters, the Trustee will vote all of the Shares in favor of, in opposition to
or abstain from the matter in the same ratio as the Trust Interests of the
Beneficiaries that returned voting instructions to the Trustee indicated
preferences for voting in favor of, in opposition to or abstaining from such
matter. The Trust Agreement also contains provisions allowing Beneficiaries to
instruct the Custodian to withdraw their allocated Trust Shares to participate
in any tender or exchange offer for the Common Stock and to make any cash or
share election, or perfect any dissenter's rights, in connection with a merger
of the Issuer.
   4
                                  SCHEDULE 13D

CUSIP No. 59156R108                                           Page 4 of 9 Pages


            A "Beneficiary Consent Matter" is:

(i)   a contested election of directors or, subject to certain conditions,
      the removal of a director,

(ii)  a merger or consolidation, a sale, lease or exchange of all or
      substantially all of the assets or a recapitalization or dissolution of
      the Issuer, if it requires a vote of stockholders under applicable
      Delaware law,

(iii) any transaction that would result in an exchange or conversion of the
      Shares for cash, securities or other property,

(iv)  issuances of Common Stock prior to the first anniversary of the effective
      date of the Plan (the "Effective Date") at a price materially below the
      prevailing market price, if a vote is required to approve the issuance
      under Delaware law, other than issuances in an underwritten public
      offering or pursuant to an employee benefit plan,

(v)   before the first anniversary of the Effective Date, any matter that
      requires approval by a vote of more than a majority of the outstanding
      stock of the Issuer entitled to vote thereon under Delaware law or the
      certificate of incorporation or the by-laws of the Issuer, and any
      amendment to the certificate of incorporation or by-laws of the Issuer
      that is submitted to a vote of stockholders for approval, and

(vi)  proposals submitted to stockholders requiring the Board of Directors to
      amend the Issuer's Stockholder Rights Plan, or redeem rights under that
      plan, other than a proposal with respect to which the Issuer has received
      advice of nationally-recognized legal counsel to the effect that the
      proposal is not a proper subject for stockholder action under Delaware
      law.

            The Trust Agreement contains provisions enabling the Beneficiaries
to withdraw the Shares allocated to them under the Plan and the Trust Agreement
for resale or otherwise and to receive dividends on such Shares.
   5
                                  SCHEDULE 13D

CUSIP No. 59156R108                                           Page 5 of 9 Pages


ITEM 5.     INTEREST IN SECURITIES OF THE ISSUER.

(a)   As an entity, the Board of Directors of the Issuer beneficially owns
      442,894,415 shares or 59.1% of the Issuer's outstanding Common Stock. The
      Board of Directors of the Issuer is deemed to beneficially own the shares
      of Common Stock held by the Trust because the Board will direct the voting
      of these shares on certain matters submitted to a vote of stockholders.
      See Item 4.

(b)   As an entity, the Board of Directors of the Issuer has shared voting power
      with respect to 442,894,415 shares of Common Stock.

(c)   Except as described in Item 4, there were no transactions in the class of
      securities reported on that were effected by the Reporting Persons since
      March 2, 2001 other than transactions by Beneficiaries under the Purchase
      and Sale Program provided for by the Trust Agreement, resulting in a
      decrease in the number of shares of Common Stock held by the Trust from
      451,365,795 to 442,894,415.

(d)   The Beneficiaries of the Trust have the right to receive or the power to
      direct the receipt of dividends from, or the proceeds from the sale of,
      the Shares allocated to them under the Plan and the Trust Agreement. See
      Item 4.
   6
                                  SCHEDULE 13D

CUSIP No. 59156R108                                           Page 6 of 9 Pages




            SIGNATURES.

            After reasonable inquiry and to the best of my knowledge and belief,
   we certify that the information set forth in this statement is true, complete
   and correct.

   Dated:  May 15, 2001



            *
------------------------------
   Robert H. Benmosche


            *
------------------------------
   Curtis H. Barnette


            *
------------------------------
   Gerald Clark


            *
------------------------------
   Joan Ganz Cooney


            *
------------------------------
   John C. Danforth


            *
------------------------------
   Burton A. Dole, Jr.


            *
------------------------------
   James R. Houghton


            *
------------------------------
   Harry P. Kamen


            *
------------------------------
   Helene L. Kaplan


            *
------------------------------
   Charles M. Leighton
   7
                                  SCHEDULE 13D

CUSIP No. 59156R108                                           Page 7 of 9 Pages


            *
------------------------------
   Stewart G. Nagler


            *
------------------------------
   John J. Phelan, Jr.


            *
------------------------------
   Hugh B. Price


            *
------------------------------
   Ruth J. Simmons


            *
------------------------------
   William C. Steere, Jr.



      * By  /s/ Gwenn L. Carr
            ------------------------
            Gwenn L. Carr
            Attorney-in-fact